LQDA stock forecast, quote, news & analysis
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease... Show more
Why Liquidia (LQDA) Stock Is Down -58% in the Last 30 Days
Key Takeaways
- LQDA fell roughly 58% over the last 30 days, from a close of $68.63 on September 3, 2026, to $28.64 on October 2, 2026.
- The collapse was triggered by a September 30 federal court ruling that Yutrepia infringes two valid claims of United Therapeutics' '327 patent.
- Rival United Therapeutics (UTHR) rallied sharply on the news, while analysts at BofA, BTIG, and Raymond James cut ratings or price targets on Liquidia.
- The court has not yet set a remedy; outcomes could range from a label change to an injunction restricting Yutrepia's availability.
- Liquidia plans to appeal the decision and to ask the FDA to remove the PH-ILD indication from Yutrepia's label.
Liquidia (LQDA) Company Overview and Market Position
Liquidia Corporation is a Morrisville, North Carolina-based biopharmaceutical company focused on developing and commercializing therapies for cardiopulmonary diseases, primarily pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's lead product, YUTREPIA, is an inhaled dry-powder formulation of treprostinil delivered through a proprietary inhaler, built on Liquidia's PRINT particle-engineering platform. Liquidia also has an investigational liposomal treprostinil formulation, L606, in its pipeline. Investors follow the stock closely because YUTREPIA represents the company's primary commercial and revenue-growth driver, making its regulatory and patent standing central to the investment case.
Liquidia (LQDA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, LQDA declined approximately 58%, dropping from a closing price of $68.63 on September 3, 2026, to $28.64 on October 2, 2026. Nearly all of that decline occurred in a single session: on September 30 the shares fell more than 50% intraday before closing at $30.26, followed by continued volatility into early October.
The broader quarterly picture reflects a longer, more gradual slide punctuated by the September collapse. LQDA traded near $84 in late July and reached intraday highs above $93 in early August before drifting lower through August and September into the mid-$60s. The September 30 patent ruling then reset the shares to roughly $30, leaving the stock down more than 60% from its late-July levels over the trailing quarter.
What Drove LQDA Stock Price in the Last 30 Days
The dominant catalyst was a September 30, 2026 ruling by the U.S. District Court in Delaware, which found that Yutrepia infringes two valid claims of United Therapeutics' '327 patent covering treatment of PH-ILD with inhaled treprostinil. The court invalidated the other four asserted claims, but the finding on the two valid claims triggered a sharp repricing of Liquidia's commercial prospects. United Therapeutics, which brought the suit, rose about 13% to 14% on the decision.
Wall Street responded quickly. BTIG downgraded Liquidia to Neutral from Buy, BofA cut its price target to $40 from $92 while maintaining a Neutral rating, and Raymond James downgraded the stock to Outperform from Strong Buy, lowering its target to $53 from $106. The sell-off reflected uncertainty over the remedy the court will impose, which could range from removing the PH-ILD indication from Yutrepia's label to an injunction restricting the drug's availability.
What Drove LQDA Stock Performance Over the Last Quarter
The quarterly decline reflects a gradual loss of momentum followed by an abrupt legal reset. After trading in the $80 to $93 range through early August, LQDA softened into the fall as investors weighed the ongoing patent litigation against United Therapeutics and the stock's rich valuation relative to its still-early commercial ramp. The September 30 ruling crystallized that risk, compressing the shares to levels far below even the reduced analyst price targets. Despite the sharp drawdown, Liquidia's longer-term return profile remained positive at the time of the decline, reflecting the substantial gains the stock had accumulated in prior years before this legal setback.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of top-performing AI trading bots drawn from a platform that offers hundreds of automated strategies trading thousands of tickers. Rather than listing every available bot, the section highlights those that are most relevant and currently performing well. The bots vary widely in trading strategy, timeframe, and performance metrics, allowing users to compare approaches that range from short-term signals to longer-horizon models. For investors and traders seeking systematic, data-driven perspectives on market activity, exploring the Trending AI Robots page can be a useful starting point.
LQDA Stock Forecast Drivers: What Investors Should Watch Next
The near-term outlook hinges on the remedy the Delaware court ultimately sets for the patent infringement, with both sides having been given a short window to propose resolutions. Investors are also watching Liquidia's planned appeal and its request to the FDA to remove the PH-ILD indication from Yutrepia's label, since a label change alone could still allow the drug to be sold for PAH. Beyond the litigation, key factors include Yutrepia's commercial launch and revenue trajectory, competitive dynamics with United Therapeutics, the progress of the L606 pipeline, and any further analyst estimate revisions as new models incorporate the patent ruling. Macroeconomic and broader biotech-sector sentiment may also influence trading in the shares.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LQDA's RSI Indicator climbs out of oversold territory
The RSI Oscillator for LQDA moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LQDA as a result. In 75 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for LQDA just turned positive on October 16, 2026. Looking at past instances where LQDA's MACD turned positive, the stock continued to rise in 48 of 54 cases over the following month. The odds of a continued upward trend are 89%.
Following a +13.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where LQDA advanced for three days, in 282 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
LQDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LQDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for LQDA entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. LQDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.827) is normal, around the industry mean (11.138). P/E Ratio (24.595) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (14.286) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of particle-based vaccines and therapeutics for prevention and treatment of human disease
Industry PharmaceuticalsGeneric